Acrivon Therapeutics (NASDAQ:ACRV) Now Covered by Analysts at BMO Capital Markets

BMO Capital Markets initiated coverage on shares of Acrivon Therapeutics (NASDAQ:ACRV – Get Rating) in a research report released on Monday morning, The Fly reports. The brokerage issued an outperform rating and a $25.00 price objective on the stock.

Several other research analysts have also recently commented on ACRV. HC Wainwright started coverage on shares of Acrivon Therapeutics in a report on Thursday, April 20th. They set a buy rating and a $24.00 price target for the company. LADENBURG THALM/SH SH began coverage on shares of Acrivon Therapeutics in a research note on Thursday, April 27th. They set a buy rating and a $22.00 target price for the company. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of Buy and a consensus price target of $22.60.

Get Acrivon Therapeutics alerts:

Acrivon Therapeutics Trading Up 1.4 %

Acrivon Therapeutics stock opened at $12.71 on Monday. Acrivon Therapeutics has a 52-week low of $8.06 and a 52-week high of $25.47. The business’s 50 day simple moving average is $14.09.

Institutional Investors Weigh In On Acrivon Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ACRV. RA Capital Management L.P. acquired a new stake in shares of Acrivon Therapeutics during the fourth quarter worth about $55,417,000. Sands Capital Ventures LLC acquired a new position in Acrivon Therapeutics during the fourth quarter worth approximately $19,038,000. Marshall Wace LLP purchased a new stake in Acrivon Therapeutics in the fourth quarter valued at approximately $14,092,000. NEA Management Company LLC acquired a new stake in shares of Acrivon Therapeutics in the fourth quarter valued at approximately $4,439,000. Finally, HealthCor Management L.P. purchased a new position in shares of Acrivon Therapeutics during the fourth quarter worth approximately $3,274,000. 63.82% of the stock is owned by hedge funds and other institutional investors.

About Acrivon Therapeutics

(Get Rating)

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to specific medicine by utilizing its proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3).

Read More

• Get a free copy of the StockNews.com research report on Acrivon Therapeutics (ACRV)
• Is the Electric Vehicle Movement Losing Steam?
• 3 High-Yield Banks Insiders Are Buying 
• Will ChatGPT Be the Final Nail in the Coffin for Chegg?
• Is the Market Reacting Too Negatively to Pinterest Earnings?
• More Analysts Should See Energizer Holdings As A Buy: Here Is Why

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.